Hepatitis C genotype 2 is contracted in the same way as other genotypes, but is generally easier to treat. Treatment usually involves interferon and ribavirin, but other medications are available. Side effects may occur, and treatment duration depends on the genotype. Factors such as lower viral loads and little or no liver damage increase treatment success.
Genotype 2 is one of the six major genotypes of the hepatitis C virus (HCV). Basically, a hepatitis C genotype is simply a certain type of disease. In the United States, genotype 1 is the most common.
The symptoms of the genotype are essentially the same as those associated with other HCV genotypes. It is also contracted in the same way: by coming into contact with contaminated blood such as in blood transfusions. However, genotype 2, along with genotype 3, is generally easier to treat than genotype 1.
Genotype 2 hepatitis C has traditionally been treated with two drugs: interferon and ribavirin. Interferon is given by injection. The frequency of these injections varies, usually from one to three times a week. Ribavirin is taken in pill form, usually twice a day. Together, the two drugs form the usual combination treatment. However, additional hepatitis C medications such as sofosbuvir are available. It is important to keep in mind that the specific drug treatment for hepatitis C depends on the genotype, its severity and its complications. Therefore, treatment should be decided through careful and informed evaluation with your physician.
Unfortunately, the drugs used to treat genotype 2, as well as other hepatitis C genotypes, can cause side effects. Patients may experience flu-like symptoms and low red or white blood cell counts. Irritability and depression may also occur.
Treatment for hepatitis C usually lasts six to 12 months. The time needed for treatment depends, in part, on which genotype the individual is battling. After treatment, about 60% of patients with genotype 1 still have detectable viral loads. If a person has a detectable viral load, it means there is enough virus in the blood to be detected by a test. Only about 20% of patients with genotype 2 still have detectable viral loads after treatment.
If a person with hepatitis C has a detectable viral load after treatment, they will likely need to continue using interferon. This is often referred to as maintenance therapy. In such cases, interferon is usually taken in doses much lower than those used in the initial treatment.
Several factors influence the success of the treatment. Individuals with genotype 2 or 3 tend to fare better. Similarly, individuals with lower viral loads and little or no liver damage respond more favorably to treatment. Women, individuals under 40, and those who abstain from alcohol also experience more frequent treatment success.
Protect your devices with Threat Protection by NordVPN
